US7022683B1
(en)
|
1998-05-13 |
2006-04-04 |
Carrington Laboratories, Inc. |
Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
|
US7906143B1
(en)
*
|
1998-10-05 |
2011-03-15 |
Intellipharmaceutics Corp |
Controlled release pharmaceutical delivery device and process for preparation thereof
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP1158985B1
(fr)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
|
AR028986A1
(es)
*
|
1999-02-23 |
2003-06-04 |
Smithkline Beecham Corp |
USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
|
GB9928343D0
(en)
*
|
1999-11-30 |
2000-01-26 |
Vericore Ltd |
Addition of tetracyclines to animal foodstuffs
|
JP4965784B2
(ja)
*
|
1999-12-03 |
2012-07-04 |
ポリケム・ソシエテ・アノニム |
バイオアベイラビリティの向上した麦角アルカロイドの徐放性医薬組成物の製造法及びその組成物
|
US7771746B2
(en)
|
1999-12-03 |
2010-08-10 |
Polichem Sa |
Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
|
DK1110550T4
(da)
*
|
1999-12-22 |
2007-07-02 |
Dsm Ip Assets Bv |
Præparat omfattende ascorbinsyre som hovedbestanddel og pektin
|
US6669948B2
(en)
|
2000-02-24 |
2003-12-30 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6663890B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Metronidazole antibiotic product, use and formulation thereof
|
US6610328B2
(en)
|
2000-02-24 |
2003-08-26 |
Advancis Pharmaceutical Corp. |
Amoxicillin-clarithromycin antibiotic composition
|
US6667057B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Levofloxacin antibiotic product, use and formulation thereof
|
US7025989B2
(en)
*
|
2000-02-24 |
2006-04-11 |
Advancis Pharmaceutical Corp. |
Multiple-delayed released antibiotic product, use and formulation thereof
|
US6623758B2
(en)
|
2000-02-24 |
2003-09-23 |
Advancis Pharmaceutical Corp. |
Cephalosporin-metronidazole antibiotic composition
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US6667042B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Fluroquinilone antibiotic product, use and formulation thereof
|
CA2400818C
(fr)
*
|
2000-02-24 |
2009-01-06 |
Advancis Pharmaceutical Corporation |
Compositions antibiotiques et antifongiques
|
US6730320B2
(en)
|
2000-02-24 |
2004-05-04 |
Advancis Pharmaceutical Corp. |
Tetracycline antibiotic product, use and formulation thereof
|
US6627222B2
(en)
|
2000-02-24 |
2003-09-30 |
Advancis Pharmaceutical Corp. |
Amoxicillin-dicloxacillin antibiotic composition
|
US6991807B2
(en)
*
|
2000-02-24 |
2006-01-31 |
Advancis Pharmaceutical, Corp. |
Antibiotic composition
|
US6638532B2
(en)
|
2000-02-24 |
2003-10-28 |
Advancis Pharmaceutical Corp. |
Tetracycline—doxycycline antibiotic composition
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6663891B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Erythromyacin antibiotic product, use and formulation thereof
|
US6632453B2
(en)
|
2000-02-24 |
2003-10-14 |
Advancis Pharmaceutical Corp. |
Ciprofoxacin-metronidazole antibiotic composition
|
US6372252B1
(en)
|
2000-04-28 |
2002-04-16 |
Adams Laboratories, Inc. |
Guaifenesin sustained release formulation and tablets
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
US6955821B2
(en)
*
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
US7105174B2
(en)
*
|
2000-10-13 |
2006-09-12 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-neoplastic product, use and formulation thereof
|
US7157095B2
(en)
*
|
2000-10-13 |
2007-01-02 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release antifungal product, use and formulation thereof
|
US20020068078A1
(en)
*
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US7074417B2
(en)
*
|
2000-10-13 |
2006-07-11 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-viral product, use and formulation thereof
|
US6541014B2
(en)
*
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US20020197314A1
(en)
*
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
US7494669B2
(en)
*
|
2001-02-28 |
2009-02-24 |
Carrington Laboratories, Inc. |
Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
|
US6777000B2
(en)
*
|
2001-02-28 |
2004-08-17 |
Carrington Laboratories, Inc. |
In-situ gel formation of pectin
|
CN1499960A
(zh)
*
|
2001-03-13 |
2004-05-26 |
����˹��ҩ�﹫˾ |
时间治疗剂型
|
US7371763B2
(en)
*
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
ATE307579T1
(de)
|
2001-09-03 |
2005-11-15 |
Dsm Ip Assets Bv |
Pektin und ascorbinsäure enthaltende zusammensetzungen
|
EP1429746B1
(fr)
*
|
2001-09-28 |
2008-08-13 |
McNEIL-PPC, INC. |
Forme pharmaceutique comprenant un noyau interne et une coque externe
|
US20030229158A1
(en)
*
|
2001-09-28 |
2003-12-11 |
Chen Jen Chi |
Polymer composition and dosage forms comprising the same
|
US7122143B2
(en)
*
|
2001-09-28 |
2006-10-17 |
Mcneil-Ppc, Inc. |
Methods for manufacturing dosage forms
|
US7838026B2
(en)
|
2001-09-28 |
2010-11-23 |
Mcneil-Ppc, Inc. |
Burst-release polymer composition and dosage forms comprising the same
|
WO2003061559A2
(fr)
*
|
2001-10-12 |
2003-07-31 |
University Of Vermont And State Agricultural College |
Peptides de liaison specifiques au domaine extracellulaire de la proteine erbb2, et utilisations correspondantes
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
US20080182841A1
(en)
*
|
2001-10-29 |
2008-07-31 |
Levine Howard L |
Vaginally administered anti-dysrhythmic agents for treating pelvic pain
|
US8425892B2
(en)
*
|
2001-10-29 |
2013-04-23 |
Columbia Laboratories, Inc. |
Extended, controlled-release pharmaceutical compositions using charged polymers
|
US20030114394A1
(en)
*
|
2001-10-29 |
2003-06-19 |
Levine Howard L. |
Vaginally administered anti-dysrhythmic agents for treating pelvic pain
|
US20080108672A1
(en)
*
|
2002-01-11 |
2008-05-08 |
Bernd Riedl |
Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
US7125563B2
(en)
|
2002-04-12 |
2006-10-24 |
Dava Pharmaceuticals, Inc. |
Sustained release pharmaceutical preparations and methods for producing the same
|
US20040033257A1
(en)
*
|
2002-05-30 |
2004-02-19 |
Strides Inc. |
Pharmaceutical formulation in a drug delivery system and process for preparing the same
|
US20030232097A1
(en)
*
|
2002-06-17 |
2003-12-18 |
Strides Inc. |
Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
|
RU2005108608A
(ru)
*
|
2002-09-28 |
2005-10-27 |
МакНЕЙЛ-ППС, ИНК. (US) |
Дозированная форма немедленного высвобождения, содержащая оболочку с отверстиями
|
US20040071779A1
(en)
*
|
2002-10-09 |
2004-04-15 |
Keiser Dale Arthur |
Gelled laxative compositions
|
US20040109889A1
(en)
*
|
2002-12-04 |
2004-06-10 |
Bunick Frank J. |
Surface treatment composition for soft substrates
|
US20040114368A1
(en)
*
|
2002-12-13 |
2004-06-17 |
Shyu Shing Jy |
Light device having rotatable or movable view
|
TWI313598B
(en)
*
|
2002-12-18 |
2009-08-21 |
Wyeth Corp |
Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
|
US20040253311A1
(en)
*
|
2002-12-18 |
2004-12-16 |
Roger Berlin |
Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
|
NZ626589A
(en)
*
|
2003-02-21 |
2016-01-29 |
Resmed Ltd |
Nasal assembly
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
EP1473030B2
(fr)
*
|
2003-05-02 |
2014-05-14 |
Dexcel Ltd. |
Formulation de comprimé à libération prolongée du venlafaxine
|
DK1636585T3
(da)
|
2003-05-20 |
2008-05-26 |
Bayer Pharmaceuticals Corp |
Diarylurinstoffer med kinasehæmmende aktivitet
|
US20040241252A1
(en)
*
|
2003-05-29 |
2004-12-02 |
Abney Christopher Charles |
Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
|
US8771649B2
(en)
|
2003-05-30 |
2014-07-08 |
Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno |
Inducible release vehicles
|
CA2529984C
(fr)
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
|
JP2006528189A
(ja)
*
|
2003-07-21 |
2006-12-14 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質産物、その使用法および製剤
|
EP1648407A4
(fr)
*
|
2003-07-21 |
2011-08-31 |
Middlebrook Pharmaceuticals Inc |
Produit antibiotique, utilisation et formulation correspondantes
|
WO2005009364A2
(fr)
*
|
2003-07-21 |
2005-02-03 |
Advancis Pharmaceutical Corporation |
Produit antibiotique, utilisation et formulation associees
|
CA2533165A1
(fr)
*
|
2003-07-21 |
2005-01-27 |
Bio-Dar Ltd. |
Formes dosifiees a liberation controlee a base de gomme gellane a administrer par voie orale, une nouvelle technologie pour la retention gastrique
|
CL2004001834A1
(es)
|
2003-07-23 |
2005-06-03 |
Bayer Pharmaceuticals Corp |
Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
|
EP1653925A1
(fr)
*
|
2003-08-11 |
2006-05-10 |
Advancis Pharmaceutical Corporation |
Pastille robuste
|
JP2007502294A
(ja)
*
|
2003-08-12 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質製剤、その使用法及び作成方法
|
EP1658034A4
(fr)
*
|
2003-08-29 |
2011-06-22 |
Middlebrook Pharmaceuticals Inc |
Produit antibiotique, son utilisation et sa formulation
|
CA2538064C
(fr)
*
|
2003-09-15 |
2013-12-17 |
Advancis Pharmaceutical Corporation |
Antibiotique, son utilisation et sa formulation
|
JP2007505921A
(ja)
*
|
2003-09-19 |
2007-03-15 |
ペンウェスト ファーマシューティカルズ カンパニー |
遅延放出剤形
|
JP2007519608A
(ja)
*
|
2003-09-19 |
2007-07-19 |
ペンウェスト ファーマシューティカルズ カンパニー |
時間治療用剤形
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
AU2004308419B2
(en)
*
|
2003-12-24 |
2011-06-02 |
Victory Pharma, Inc. |
Enhanced absorption of modified release dosage forms
|
US20050181047A1
(en)
*
|
2004-02-18 |
2005-08-18 |
Jaime Romero |
Compositions and methods for timed release of water-soluble nutritional supplements
|
EP1730751B1
(fr)
*
|
2004-03-12 |
2009-10-21 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Milieu magnetoresistant
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
WO2006014427A1
(fr)
*
|
2004-07-02 |
2006-02-09 |
Advancis Pharmaceutical Corporation |
Comprimé pour distribution par impulsion
|
US20060034784A1
(en)
*
|
2004-08-12 |
2006-02-16 |
The Procter & Gamble Company |
Oral compositions and systems
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US20070077297A1
(en)
*
|
2004-09-30 |
2007-04-05 |
Scolr Pharma, Inc. |
Modified release ibuprofen dosage form
|
WO2006046954A1
(fr)
*
|
2004-10-26 |
2006-05-04 |
Mcneil-Ppc, Inc. |
Composition polymere a liberation en rafales et formes posologiques comprenant ladite composition
|
US20060093560A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Jen-Chi Chen |
Immediate release film coating
|
US20060099550A1
(en)
*
|
2004-11-10 |
2006-05-11 |
Ranir/Dcp Corporation |
Device and method for delivering an oral care agent
|
EP1830886B1
(fr)
*
|
2004-12-27 |
2016-04-13 |
Eisai R&D Management Co., Ltd. |
Methode de stabilisation d'un medicament contre la demence
|
US20060246003A1
(en)
*
|
2004-12-27 |
2006-11-02 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
US20070129402A1
(en)
*
|
2004-12-27 |
2007-06-07 |
Eisai Research Institute |
Sustained release formulations
|
US20060159753A1
(en)
*
|
2004-12-27 |
2006-07-20 |
Eisai Co. Ltd. |
Matrix type sustained-release preparation containing basic drug or salt thereof
|
US20090208579A1
(en)
*
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
US20060160852A1
(en)
*
|
2004-12-27 |
2006-07-20 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
US20060280789A1
(en)
*
|
2004-12-27 |
2006-12-14 |
Eisai Research Institute |
Sustained release formulations
|
US20080118564A1
(en)
*
|
2005-01-26 |
2008-05-22 |
Lek Pharmaceuticals D.D |
Pharmaceutical Composition Containing Candesartan Cilexetil as Lipophilic Crystalline Substance
|
US20060275364A1
(en)
*
|
2005-05-26 |
2006-12-07 |
Ahmed Salah U |
Flexible Solid Dosage Forms and Methods of Making and Using the Same
|
US20070036859A1
(en)
*
|
2005-08-11 |
2007-02-15 |
Perry Ronald L |
Sustained release antihistamine and decongestant composition
|
US20080274180A1
(en)
*
|
2005-08-30 |
2008-11-06 |
Nicholas Piramal India Limited |
Extended Release Pharmaceutical Composition of Metformin and a Process for Producing It
|
WO2007056205A2
(fr)
*
|
2005-11-04 |
2007-05-18 |
Eastman Chemical Company |
Esters de carboxyalkylcellulose pour administration d'agents pharmaceutiquement actifs peu solubles
|
US8778924B2
(en)
*
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
EP1988880A2
(fr)
*
|
2006-02-15 |
2008-11-12 |
Tika Läkemedel AB |
Mélange de corticostéroïdes stable
|
EP2428205B1
(fr)
|
2006-03-16 |
2012-10-03 |
Tris Pharma, Inc. |
Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions
|
US9561188B2
(en)
*
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
AU2007268240B2
(en)
*
|
2006-05-23 |
2012-12-06 |
Orahealth Corporation |
Xylitol troches and methods of use
|
NZ573174A
(en)
*
|
2006-06-01 |
2012-01-12 |
Msd Consumer Care Inc |
Sustained release pharmaceutical dosage form containing phenylephrine
|
EP2034970B1
(fr)
*
|
2006-06-01 |
2012-08-01 |
MSD Consumer Care, Inc. |
Formulations pharmaceutiques de phényléphrine et compositions pour absorption par le côlon
|
ES2400446T5
(es)
|
2006-08-03 |
2017-03-13 |
Horizon Pharma Ag |
Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática
|
US7749537B2
(en)
*
|
2006-12-04 |
2010-07-06 |
Scolr Pharma, Inc. |
Method of forming a tablet
|
WO2008105920A1
(fr)
*
|
2007-02-28 |
2008-09-04 |
Collegium Pharmaceutical, Inc. |
Combinaison d'antihistaminiques
|
WO2010084188A1
(fr)
*
|
2009-01-26 |
2010-07-29 |
Nitec Pharma Ag |
Traitement de l'asthme par glucocorticoïde à libération retardée
|
NZ582836A
(en)
*
|
2009-01-30 |
2011-06-30 |
Nitec Pharma Ag |
Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
EP2421524B1
(fr)
|
2009-04-20 |
2018-08-08 |
Elcelyx Therapeutics, Inc. |
Thérapies à base de ligand de récepteur chimiosensible
|
US8828953B2
(en)
*
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
EP3064064A1
(fr)
*
|
2009-09-30 |
2016-09-07 |
Acura Pharmaceuticals, Inc. |
Procédés et compositions de dissuasion d'abus
|
US20110274811A1
(en)
*
|
2010-05-06 |
2011-11-10 |
Mark Edward Hines |
Cellulose gums with reduced variabililty and method for producing same
|
US8241680B2
(en)
|
2010-06-30 |
2012-08-14 |
Rock Creek Pharmaceuticals, Inc. |
Nutraceutical product containing anatabine and yerba maté
|
KR20130091760A
(ko)
|
2010-08-20 |
2013-08-19 |
더 유니버시티 오브 유타 리서치 파운데이션 |
약물 및 다른 물질의 질내 전달용 장치 및 방법
|
KR20140114736A
(ko)
|
2010-10-19 |
2014-09-29 |
엘셀릭스 테라퓨틱스 인코포레이티드 |
화학감각 수용체 리간드-기반 요법
|
EP2651400B2
(fr)
|
2010-12-16 |
2023-01-18 |
Amgen (Europe) GmbH |
Formes posologiques pour des médicaments peu solubles administrés par voie orale à libération contrôlée et leurs utilisations
|
US9532977B2
(en)
|
2010-12-16 |
2017-01-03 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
HUE051738T2
(hu)
|
2011-01-07 |
2021-03-29 |
Anji Pharma Us Llc |
Kemoszenzoros receptorligandum-alapú terápiák
|
CN108578405A
(zh)
|
2011-08-29 |
2018-09-28 |
菲利普莫里斯产品有限公司 |
用于抗炎支持的产品
|
EP2704696A1
(fr)
|
2012-03-26 |
2014-03-12 |
Glatt AG |
Granulés d'ibuprofène de saveur masquée
|
WO2013158928A2
(fr)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Thérapies à base de ligand de récepteur chimiosensoriels
|
CN107595793B
(zh)
|
2012-11-30 |
2020-11-13 |
阿库拉制药公司 |
活性药物成分的自调节释放
|
GB201316857D0
(en)
*
|
2013-09-23 |
2013-11-06 |
Buckley Howard |
Composition for the oral delivery of compounds
|
CA2943728C
(fr)
|
2014-03-26 |
2020-03-24 |
Sun Pharma Advanced Research Company Ltd. |
Forme galenique solide de matrice biphasique a liberation immediate et dissuasive d'abus
|
US9617230B2
(en)
|
2014-12-22 |
2017-04-11 |
Farmington Pharma Development |
Creatine prodrugs, compositions and methods of use thereof
|
WO2017040607A1
(fr)
|
2015-08-31 |
2017-03-09 |
Acura Pharmaceuticals, Inc. |
Procédés et compositions pour la libération auto-régulée d'un ingrédient pharmaceutique actif
|
US11278506B2
(en)
|
2015-10-09 |
2022-03-22 |
Rb Health (Us) Llc |
Pharmaceutical formulation
|
WO2017083348A1
(fr)
|
2015-11-11 |
2017-05-18 |
Celgene Corporation |
Formes pharmaceutiques orales à libération contrôlée de médicaments faiblement solubles et leurs utilisations
|
EP3600440A1
(fr)
|
2017-03-20 |
2020-02-05 |
Sienna Biopharmaceuticals, Inc. |
Conjugués d'exposition réduite modulant des cibles thérapeutiques
|
US20210113475A1
(en)
*
|
2017-04-18 |
2021-04-22 |
Sensient Colors Llc |
Dosage form coating composition and method of making and using the same
|
MX2020005707A
(es)
|
2017-12-01 |
2020-08-20 |
Ultragenyx Pharmaceutical Inc |
Profarmacos de creatina, composiciones y metodos de uso de estos.
|
MX2020005518A
(es)
|
2017-12-05 |
2020-11-06 |
Sunovion Pharmaceuticals Inc |
Mezclas no racemicas y usos de las mismas.
|
JP2021505595A
(ja)
|
2017-12-05 |
2021-02-18 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
結晶形およびその製造方法
|
PL3898607T3
(pl)
|
2018-12-17 |
2024-03-18 |
Philip Morris Products S.A. |
Glutaran 3-(1,2,3,6-tetrahydropirydyn-2-ylo)pirydyny lub jego farmaceutycznie dopuszczalny solwat
|
JP2022535893A
(ja)
|
2019-06-04 |
2022-08-10 |
サノビオン ファーマシューティカルズ インク |
放出調節製剤およびその使用
|
WO2023154464A1
(fr)
*
|
2022-02-11 |
2023-08-17 |
Fairleigh Dickinson University |
Compositions administrées localement et leurs méthodes d'utilisation
|